关于抗抑郁药相关不良反应的VigiBase药监测研究:一个范围审查
概括
在VigiBase中对心理药物不良反应 (ADRs) 的药监测研究显示,抗精神病药物,特别是克洛札,是最常见的. 对抗抑郁药物的副作用进行了审查,以证明风险沟通.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 药学流行病学 药学流行病学
背景情况:
- 世界卫生组织的全球药监数据库VigiBase存储了数以百万计的药物不良反应 (ADR) 报告.
- 药物监测对于检测,评估和沟通与药物相关的危害至关重要.
- 由于其广泛使用,精神药物经常受到安全性监测.
研究的目的:
- 分析过去五年在VigiBase中报告的与精神药物相关的副作用的趋势.
- 确定心理药物副作用中最常见的类别和特定药物.
- 为了说明识别和沟通药物风险的过程,使用抗抑郁药物不良反应作为案例研究.
主要方法:
- 在VigiBase数据库中系统搜索心理药物不良反应的药监测研究.
- 分析报告的副作用,按药物类别和特定药物分类.
- 详细审查与抗抑郁药相关的ADR报告的一个子集.
主要成果:
- 与抗精神病药物相关的ADR构成了VigiBase中大多数精神药物ADR报告.
- 与克洛扎相关的不良反应在抗精神病类药物中最为普遍.
- 九份与抗抑郁药相关的ADR报告被选中进行深入检查.
结论:
- 抗精神病药物,特别是克洛扎宾,与大量报告的副作用有关.
- 像VigiBase这样的药监系统对于识别和管理药物安全信号至关重要.
- 对抗抑郁药物的ADRs的详细审查强调了药物监测在风险沟通中的实际应用.
更多相关视频
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
50
04:33Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
679
相关概念视频
Pharmacovigilance
833
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
833
Antidepressant Drugs: MAOIs and Other Agents
229
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
229
Antidepressant Drugs: Overview
485
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
485
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
388
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
388
Antiepileptic Drugs: Potassium Channel Activators
183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
183
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252
